Read + Share
Amedeo Smart
Independent Medical Education
Xin H, Zhang C, Ding Z, Zhang M, et al. TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports. Clin Res Hepatol Gastroenterol 2022;46:101777.PMID: 34333197
Email
LinkedIn
Facebook
Twitter
Privacy Policy